An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic

Targeting kinases is central to drug-based cancer therapy but remains challenging because the drugs often lack specificity, which may cause toxic side effects. Modulating side effects is difficult because kinases are evolutionarily and hence structurally related. The lack of specificity of the antic...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Fernández, Ariel, Sanguino, Angela, Peng, Zhenghong, Ozturk, Eylem, Chen, Jianping, Crespo, Alejandro, Wulf, Sarah, Shavrin, Aleksander, Qin, Chaoping, Ma, Jianpeng, Trent, Jonathan, Lin, Yvonne, Han, Hee-Dong, Mangala, Lingegowda S., Bankson, James A., Gelovani, Juri, Samarel, Allen, Bornmann, William, Sood, Anil K., Lopez-Berestein, Gabriel
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2007
Assuntos:
Technical Advance
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2104494/
https://ncbi.nlm.nih.gov/pubmed/18060038
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI32373
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados